Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.

Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D.

Front Pharmacol. 2016 Aug 4;7:239. doi: 10.3389/fphar.2016.00239. eCollection 2016.

PMID:
27540363
Free PMC Article
2.

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.

Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M; IMPAACT P1026s Protocol Team.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):289-96. doi: 10.1097/QAI.0000000000000968.

PMID:
26918544
3.

Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.

Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A.

Clin Infect Dis. 2016 Mar 15;62(6):761-9. doi: 10.1093/cid/civ991. Epub 2015 Dec 9.

PMID:
26658057
4.

The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.

Cotton MF, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20271. doi: 10.7448/IAS.18.7.20271. eCollection 2015.

5.

Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.

Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M; PANNA Network and the IMPAACT 1026 Study Team.

Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22.

PMID:
26202768
6.

Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.

Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):33-41. doi: 10.1097/QAI.0000000000000668.

PMID:
25950206
7.

Designing drug trials: considerations for pregnant women.

Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M.

Clin Infect Dis. 2014 Dec 15;59 Suppl 7:S437-44. doi: 10.1093/cid/ciu709.

8.

Can traditional birth attendants be trained to accurately identify septic infants, initiate antibiotics, and refer in a rural African setting?

Gill CJ, MacLeod WB, Phiri-Mazala G, Guerina NG, Mirochnick M, Knapp AB, Hamer DH.

Glob Health Sci Pract. 2014 Aug 31;2(3):318-27. doi: 10.9745/GHSP-D-14-00045. eCollection 2014 Aug.

9.

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.

Cressey TR, Urien S, Capparelli EV, Best BM, Buranabanjasatean S, Limtrakul A, Rawangban B, Sabsanong P, Treluyer JM, Jourdain G, Stek A, Lallemant M, Mirochnick M.

J Antimicrob Chemother. 2015 Jan;70(1):217-24. doi: 10.1093/jac/dku367. Epub 2014 Sep 25.

10.

Raltegravir pharmacokinetics in neonates following maternal dosing.

Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.

11.

Raltegravir pharmacokinetics during pregnancy.

Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M; IMPAACT 1026s study team.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):375-81. doi: 10.1097/QAI.0000000000000318.

12.

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):33-41. doi: 10.1097/QAI.0b013e3182a921eb.

13.

Raltegravir in vitro effect on bilirubin binding.

Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M.

Pediatr Infect Dis J. 2013 Sep;32(9):978-80. doi: 10.1097/INF.0b013e31829044a8.

14.

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66. doi: 10.1097/QAI.0b013e318289b4d2.

15.

Reduced indinavir exposure during pregnancy.

Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M; IMPAACT P1026s team.

Br J Clin Pharmacol. 2013 Sep;76(3):475-83. doi: 10.1111/bcp.12078.

16.

Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.

Fogel JM, Mwatha A, Richardson P, Brown ER, Chipato T, Alexandre M, Moodley D, Elbireer A, Mirochnick M, George K, Mofenson LM, Zwerski S, Coovadia HM, Eshleman SH.

Pediatr Infect Dis J. 2013 Apr;32(4):e164-9. doi: 10.1097/INF.0b013e31827f44ee.

17.

Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.

Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado D, Bethel J, Morgado MG, Dickover R, Camarca M, Mirochnick M, Siberry G, Grinsztejn B, Moreira RI, Bastos FI, Xu J, Moye J, Mofenson LM; NICHD HPTN 040/PACTG 1043 Protocol Team.

N Engl J Med. 2012 Jun 21;366(25):2368-79. doi: 10.1056/NEJMoa1108275.

18.

Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants.

Fogel JM, Taha TE, Sun J, Hoover DR, Parsons TL, Kumwenda JJ, Mofenson LM, Fowler MG, Hendrix CW, Kumwenda NI, Eshleman SH, Mirochnick M.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):462-5.

19.

Targeted echocardiography in the neonatal intensive care unit.

Sinha B, Mirochnick MH, Kumar S, Fujii AM.

J Am Soc Echocardiogr. 2012 Mar;25(3):361; author reply 361-2. doi: 10.1016/j.echo.2012.01.001. Epub 2012 Jan 31. No abstract available.

PMID:
22297083
20.

Developmental pharmacokinetic changes of Lamivudine in infants and children.

Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV.

J Clin Pharmacol. 2012 Dec;52(12):1824-32. doi: 10.1177/0091270011426563. Epub 2011 Dec 16.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk